Investors

Pioneering a Curative Approach to Autoimmune and Infectious Diseases

ImmuPharma PLC (LSE: IMM) is a clinical-stage biopharmaceutical company developing first-in-class peptide-based therapies and precision diagnostics to transform the treatment of autoimmune diseases and infectious diseases.

Our ambition is bold:

to move beyond symptom management and build therapies that aim for remission — and ultimately, cure.

Share Price

A Clear Strategic Vision

The current standard of care in autoimmune disease focuses on controlling inflammation rather than addressing its root cause. ImmuPharma is pioneering a new therapeutic paradigm through its proprietary P140 platform:

Restoring immune tolerance instead of broad suppression
Identifying and targeting the right patients through companion diagnostics
Building a precision medicine ecosystem that enables durable remission

This differentiated approach positions ImmuPharma as a leader in the next wave of immunology innovation.

A Differentiated Pipeline with Global Potential

ImmuPharma’s portfolio is built around two pillars: autoimmunity and anti-infectives, with multiple value drivers:

P140 (Lupuzor™): A first-in-class immune normalizer. Unlike current therapies, P140 corrects underlying immune dysregulation while preserving healthy immune function.
Type M Diagnostic Platform: A next-generation companion diagnostic identifying “super-responder” patients across major autoimmune indications, enabling precision medicine.
Pipeline expansion: P140 platform shows potential in multiple autoimmune diseases.
Anti-infectives (BioAMB & BioCIN): Next-generation therapies designed to tackle global resistance challenges in critical fungal and bacterial infections.

P140

Autoimmunity

Clinic

CDx

Autoimmunity

Clinic

BioAMB

Antifungal

Preclinic

BioCIN

Antibiotic

Preclinic

Strategic Partnerships and IP Strength

Robust patent estate with protection expected until 2045.
A scalable peptide-based platform with multiple partnering opportunities across therapeutic areas.

Why Invest in ImmuPharma?

A unique curative vision in autoimmune diseases — a shift away from conventional immunosuppression.
First-in-class therapeutic and diagnostic platform enabling precision medicine.
Clinical asset (P140) and near-term development catalysts.
Expanding pipeline in both autoimmune and anti-infective markets with high unmet need.
Strong IP protection and an established partnership with Avion Pharmaceuticals.

Creating Sustainable Value

ImmuPharma is entering a new phase of growth, leveraging its scientific leadership and strategic partnerships to unlock significant value for patients and shareholders alike.

We’re not just developing new drugs — we’re redefining how autoimmune and infectious diseases are treated.

Professional advisers

Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
5 St. John’s Lane
London
EC1M 4BH
www.sparkadvisorypartners.com

Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us

Joint Broker
Si Capital Limited
46 Bridge St
Godalming
GU7 1HL
info@sicapital.co.uk

Public Relations & Investor Relations
lisa.baderoon@immupharma.com

Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street
London
EC2R 8LA
www.rbs.co.uk

Auditors
Crowe LLP
55 Ludgate Hill
London
EC4M 7JW
www.crowe.com/uk

Legal Representatives
Broadfield UK
One Bartholomew Close
London
EC1A 7BL
www.broadfield-law.com

Patent Agents
Haseltine Lake Kempner LLP
7th Floor, Cheapside House
138 Cheapside
London
EC2V 6BJ
www.hlk-ip.com

Registrars
Computershare Investor Services PLC
PO Box 82 The Pavilions
Bridgewater Road
Bristol
BS99 7NH
www.computershare.com

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.